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What is already known: 
• People with type 2 diabetes mellitus are at an elevated risk of being affected by cardiovascular 
disease (CVD).  
• CVD is the leading cause of comorbidity and death among people with type 2 diabetes 
• Cost comparisons are usually between two groups of people with type 2 diabetes: with and 
without CVD 
• The majority of studies take a CVD prevalence-based approach to estimating the cost of 
illness 
 
What this study adds: 
• We present both, costs associated with prevalent CVD for three groups of people with type 2 
diabetes and costs associated with incident CVD over a three-year period. 
• The mean annual healthcare costs per person without CVD was £2,500, for a people at high 
risk of future CVD £3,300 and for a person with established CVD £6,900 
• Total mean costs over three years following an incident CVD event were £25,000 vs. £5,900 
for people with type 2 diabetes without an incident CVD event 
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There is a lack of generalisable studies based on large national population datasets on the economic 
burden of cardiovascular disease (CVD) in people with type 2 diabetes. Our study aims are twofold: 
we compare costs for three groups of people with type 2 diabetes: those at high risk of future CVD, 
those without CVD and those with established CVD. We also estimate costs incurred by people with 
type 2 diabetes with an incident CVD event and compare to those who remain incident event free 
over a three-year period. 
Methods 
Data about people with type 2 diabetes in Scotland were obtained from the Scottish Care 
Information Diabetes registry. Data linkage was used to retrieve information on healthcare 
utilisation, care home use and deaths. Productivity effects were estimated for those of non-
pensionable age. We estimated costs over 12 months (prevalent CVD) and three years from incident 
CVD event. 
Results  
Mean annual cost per person with established CVD was £6,900, £3,300 for a person at high risk of 
future CVD and £2,500 for a person without CVD and not at high risk. In year one, the cost of an 
incident CVD event was £16,700 compared to £2,100 for people without an incident event. Over two 
years, the cumulative costs were £21,500 and £4,200, and by year three, £25,000 and £5,900 
respectively. 
Conclusions 
Cardiovascular disease in people with type 2 diabetes places a significant financial burden on health 












Cardiovascular disease (CVD) is the leading cause of comorbidity and death among people with type 
2 diabetes mellitus [1]. People with type 2 diabetes are at increased risk and are disproportionally 
affected by cardiovascular disease (CVD) [2-5]. In addition to a reduction in quality of life and life 
expectancy, morbidity associated with CVD places significant burden on health services and the 
wider economy, highlighted in a recent systematic review on the economic burden of CVD among 
people with type 2 diabetes [6]. This review concluded that only few of the studies included 
productivity costs.[6] The majority of studies were undertaken over a decade ago, however the 
treatment landscape in type 2 diabetes changes rapidly. In addition, comparisons that have been 
made in the literature were between people with and without CVD. Prevention is also important and 
hence, inclusion of a third group i.e., people at high risk of developing CVD will add significantly to 
the existing evidence on costs associated with prevalent CVD in people with type 2 diabetes. In 
addition, it is not known how costs and the composition of these develop over time after an incident 
CVD event.   
 
Therefore, this study aims to provide a comprehensive analysis of both, the cost of prevalent and 
incident CVD in people with type 2 diabetes. For prevalent CVD, we compare the cost of illness for a 
12 months period for three groups of people with type 2 diabetes: those with no CVD, those at high 
risk of developing CVD, and those with established CVD. The second analysis compares costs 
incurred by people with type 2 diabetes who experience an incident CVD event to those who remain 
CVD event free over a three-year period. We will also provide evidence on the composition of overall 
costs over that time period.   
 
Methods 
Data Sources  
We utilised the population-wide Scottish Care Information – Diabetes (SCI-Diabetes) database to 
obtain information about people with type 2 diabetes [7]. SCI-Diabetes is a real-time clinical 
information system tracking clinical information with more than 99% case ascertainment. It also 
contains socio-demographic and prescribing data. The Community Health Index (CHI), a universal 
national health service identifier, allowed us to link individual patient-level data on inpatient 





Using a cross-sectional study design, we included all people with type 2 diabetes who were alive on 
1 July 2015. Based on a 10-year lookback period people were classified into three groups: i) having 
established CVD, ii) being at high risk of future CVD and iii) being CVD free and not at high risk of 
future CVD. Observations were censored at death or on incident CVD event. Prevalent CVD was 
established using inpatient admission and primary care records (see supplementary material for ICD-
10 codes). Risk of future CVD was defined using SCI-Diabetes and primary care records (Read codes) 
if patients over the age of 60 years  also met one of the following criteria: duration of type 2 
diabetes for more than 5 years, HbA1c>9%, hypertension (defined as blood pressure >130/80 mm 
Hg (if no formal diagnosis of hypertensive disease)), dyslipidaemia (defined as total cholesterol >9.0 
mmol/l, non-HDL >7.5 mmol/l, triglycerides 4.5-9.9 mmol/l, pure hypercholesterolemia (E78.0), pure 
hyperglyceridemia (E78.1), mixed hyperlipidemia (E78.2), other hyperlipidemia (E78.4), unspecified 
hyperlipidemia (E78.5), other lipoprotein metabolism disorders (E78.89), unspecified disorder of 
lipoprotein metabolism (E78.9)), albuminuria, smoking status (smoker vs. non-smoker), BMI 
>30kg/m2, >2 drugs specific to CVD, eGFR<60 ml/min/1.73m2, diabetic retinopathy, left ventricular 
dysfunction, left ventricular hypertrophy or angina. For these variables, values that were nearest to 
1st January were used with a lookback period of two years and the most recent value was used for 
each individual [8].  
 
Incident CVD 
People alive with type 2 diabetes at any point between 1 January 2010 and 30 June 2015 were 
included and followed up for a maximum of three years during which occurrence of the first CVD 
event was recorded. A 10-year lookback period was used to exclude people with a previous history 
of CVD. CVD events were defined using standard definitions as defined for the prevalent cohort 
above [8]. Observations were censored at death or end of study (June 2016). For people not 
experiencing a CVD event during follow-up, the study mid-point (2013) was used as their inception 
date, allowing for the maximum follow-up of three years.  
 
Health and Social Care Utilisation 
Inpatient admissions and day cases including information on diagnostic codes (ICD-10), length of 
acute hospital stay, speciality, health board area and discharge destination were obtained from 
Scottish Morbidity Records (SMR01) [9]. Per diem costs [10] for 2015/2016 were obtained from the 
Scottish Health Service Costs (‘Cost Book’ (R040)) and mapped to health board and specialty. 
Prescribing data were retrieved from SCI-Diabetes. Unit costs per prescription were obtained from 
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the Information Services Division (ISD) [11] and were assigned to prescribed items using British 
National Formulary (BNF) codes. To derive an estimation of annual frequency of primary care visits 
we used a validated algorithm based on the Charlson Comorbidity Index (CCI). [12] Primary care 
costs were assigned to each visit using published costs from the Personal Social Services Research 
Unit [13]. Dependency status was derived from the discharge destination in SMR01. The Scottish 
Care Home census confirms that, once admitted to a care home only 5% of patients return to 
independent living. [14] Therefore, we applied 95% of the mean weekly care costs to all patients in 
care homes for the duration of the study or until death. [15] For people of working age we applied a 
weekly cost of £560 [16] (average adult wage) for the duration that patients were either in hospital 




Generalised Linear Models (GLM) with a gamma distribution and an identity link function were 
employed to estimate the contribution of different cost categories to total costs for each of the 
three groups. No imputation was carried out in cases of missing data items except for comorbidity. 
We adjusted for clinical (duration of diabetes, blood pressure, HbA1c, total cholesterol and CCI) and 
demographic (age, sex, Scottish Index of Multiple Deprivation (SIMD) [17]) factors. Mean annual 
costs for prevalent CVD over a 12 months period and confidence intervals were obtained from 
predicted values of these regression models. Similarly, we obtained mean costs for year one, two 
and three since incident CVD event. All cost estimates were reported in 2015/16 prices. All analyses 




Of 244,752 people alive with type 2 diabetes as of 1 July 2015 (median duration of diabetes 7.7 
years), we identified 73,037 people with type 2 diabetes with established CVD, 141,428 at high risk 
of CVD and 30,287 with no CVD and not at high risk (Table A1, supplementary online material). The 
mean annual cost for a person without CVD and not at high risk was £2,500 (95%CI: £700 - £8,000), 
£3,300 (95%CI: £1,000 - £16,100) for a person at high risk of future CVD and £6,900 (95%CI:£1,600 - 
£29,700) for a person with established CVD (Table 1). This pattern of increasing costs in connection 
with CVD was observed across all age groups. Across (non-exclusive) CVD categories and excluding 
the small number of people with hypertensive diseases, people with peripheral arterial disease and 
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heart failure as their first event incurred the highest costs over the 12 months study period and 
those that underwent revascularisation procedures the lowest (Table 2). However, the wide 




For people with established CVD, hospital admissions accounted for the majority of annual costs 
(Figure 1). Costs related to hospital admission accounted for a smaller share of overall costs for 
people with no CVD, with prescription and primary care costs accounting for a larger proportion of 
total costs compared to people with established CVD (Figure 1). The distribution of individual cost 
elements for people at high risk of CVD is similar to that of people with no CVD except their hospital 
costs represented a greater share of overall costs and primary care costs a smaller share. Indirect 
costs due to lost productivity was found to be a very small component of overall costs for all groups 
(0.2% across all three groups). A breakdown of costs by CVD type and healthcare sector is provided 







Our analysis included 245,428 people with type 2 diabetes with no previous history of CVD, 35,322 
of whom experienced an incident CVD event during follow-up. Baseline characteristics are shown in 
Table A2 (online supplementary material). We present mean annual costs by subgroups of age and 
type of CVD incident event in Table 3 alongside three-year mortality and incidence rates. People 
experiencing an incident event were nine years older on average compared to individuals not 
experiencing a CVD event (Table A2). These people have also had their type 2 diabetes diagnosis for 
longer.  
 
Mean costs per person after three years since the incident CVD event (£25,000) compared to costs 
for individuals, who do not experience an incident CVD event (£5,900) were substantially higher 
(Table 3). Although costs in year one include those incurred during the incident event, we find that 
this pattern persists and also that costs generally increase with increasing age. Cerebrovascular 
incident events were associated with the highest cost over three years (£37,900) and 
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revascularisation procedures were associated with the lowest cost (£17,500). Large cost increments 
between year one and three were found for transient ischaemic attack (TIA), where by year three 
costs had doubled compared to those incurred in year one since incident event. A different pattern 
is observed for incident events that may require a higher upfront cost, such as revascularisation 
procedures, where costs after three years show a smaller increase (Table 4). The overall CVD event 
rate was 30.81 per 1,000 person-years and was found to be highest for Ischaemic Heart Disease 
(15.35 per 1,000 person-years). The CVD categories in Table 4 are not exclusive, people may be 




In the 12 months period following the incident CVD event, hospital and residential care costs 
accounted for the largest share of total costs. In years 2 and 3, residential and primary care 
accounted for a larger proportion than in year one, with hospital care still being the main 
contributor (Figure 2). Prescription costs remained relatively proportionately constant over time for 
individuals experiencing an incident CVD event, but proportionately reduced in relation to other cost 
categories for those without an event, while hospital costs increased. For both groups, costs 
associated with lost productivity only accounted for one to two percent of total costs. (Figure 2). All 
analyses were age-adjusted. 
 
Sector-specific costs by type of incident CVD event and year are presented in Table 5. Figure A1 
(online supplementary material) provides an overview of the sector-specific cost contributions to 
overall costs at 3 years for people who experienced an incident event (Figure A1). People without a 
CVD event incurred costs distributed evenly between primary, hospital, residential care and 
prescriptions. With the exception of hypertensive diseases, the distribution of cost categories is very 







Prevalent and incident CVD in people with type 2 diabetes place a significant financial burden on 
health and social care services and the wider economy. Using national population level data, we 
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identified both, prevalent CVD and incident CVD events in people with type 2 diabetes and 
estimated costs to the healthcare system and the wider economy. The magnitude of that burden 
varies between groups. Our findings suggest that a person with type 2 diabetes at high CVD risk 
costs the economy an additional £900 per year on average compared to a person with type 2 
diabetes not at high risk. If CVD is present the additional annual cost rises to£4,400, excluding the 
costs associated with earlier CVD event(s).  
 
To date, only a limited number of UK studies have analysed the economic burden of CVD in people 
with type 2 diabetes. [19,20] Hex et al reported costs for hospital admission and procedures at a 
population [19] and Alva et al [20] at an individual level. In comparison to our study the sample sizes 
were smaller and CVD categories differed. However, in terms of secondary care costs in the first year 
it is possible to make comparisons. For ischaemic heart disease, Alva et al. report a cost of £9,800 in 
2012 prices (£10,100 inflated using the Hospital and community service index), which is close to our 
estimate of £11,000.   
 
Rather than just comparing between people with and without CVD, we were able to identify a third 
group of people with type 2 diabetes at high risk of future CVD, thus providing a more 
comprehensive picture. 
 
The type of incident CVD event also impacts on costs and the highest costs are incurred during the 
incident event.  However substantial cost differentials between people with type 2 diabetes with 
and without CVD event continue to show beyond incident event over a three-year follow-up. This 
seems to be caused by the initial high costs associated with the incident event and by complications 
that develop once CVD is established. The composition of overall costs changes over a three-year 
follow-up for people with type 2 diabetes with an incident CVD event with hospital costs decreasing, 
and costs for residential care increasing over time. For people who remained CVD event free over a 
three-year period, hospital costs increased, whereas prescription costs decreased. Costs due to lost 
productivity are small, as a majority of patients is above pensionable age. We expanded on earlier 
research which reported overall annual costs of $3,400 and $9,700 for treating people with type 2 
diabetes and CVD compared to those without CVD [6]. Our estimated cost differences were higher 
than those reported in the systematic review, however, most studies only considered direct costs 




Strengths and Limitations 
We were able to include all main cost components for direct and indirect medical costs, estimated 
costs due to lost productivity and costs for care home stays.  However, we appreciate that there may 
be uncertainty, in particular around the frequency of primary care contacts, as these were estimated 
using an existing algorithm from the literature and around costs due to lost productivity as the 
estimation relied on the assumption that only a hospitalisation would lead to days of work lost. 
Using a contemporary and representative cohort we were able to quantify the financial burden of 
CVD in type 2 diabetes, emphasising the importance of effective prevention strategies and providing 
guidance to inform risk stratification to guide treatment decisions. 
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Costs (£) over 12 months 
per patient 
Mean (95% CI) 
        
All 
(n=244,752) 





 70-79 years 
(n=64,839) 





 6,900 (1,600 – 29,700) Established 
(n=10,024) 















 10,100 (2,100 – 40,400) 
High Risk 
(n=141,428) 
 3,300 (1,000 – 16,100) High Risk 
(n=49,094) 













 7,100 (1,800, - 38,800) 
None 
(n=30,287) 
 2,500 (700 – 8,000) None 
(n=12,937) 













 5,900 (1,300 – 36,600) 
 
Table 2: Total mean cost for people with type 2 diabetes in Scotland for 2015-2016 by CVD type (rounded to the nearest £100) 
First CVD event N Costs (£) over 12 months per patient 
Mean (95% CI) 
Ischaemic Heart Disease  44,948 5,800 (1,500 – 26,300) 
Heart Failure 2,736 8,600 (1,500 – 38,300) 
Cardiac Arrhythmia  9,855 8,100 (2,000 – 34,000) 
Cerebrovascular Disease or Transient Ischaemic Attack  8,451 5,800 (1,400 – 21,700) 
           Cerebrovascular Disease  6,123 7,900 (1,900 – 32,000) 
           Transient Ischaemic Attack  2,328 6,200 (1,600 -  35,700) 
Peripheral Arterial Disease  3,938 9,200 (1,800 – 40,900) 
Revascularisation Procedures  3,104 4,700 (1,300 – 20,600) 





Caption for Figure 1. Contribution of cost categories to average total annual costs for patients with 
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Residential Care Productivity Lost
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Table 3: Annual Costs by Cost Component and First CVD Type for people with type 2 diabetes in 
Scotland for 2015-2016 (rounded to the nearest £100) 
 Costs (£) over 12 months - Mean (95% CI) 
CVD type Secondary care  Primary care  Residential 
care* 
Prescriptions  Productivity*  
Cardiac Arrhythmia n=9,855 
 
 
6,000 (60 – 
53,300) 
 
700 (175 – 
1,300) 
 
400 (0 – 1,400) 
 
1,000 (0 – 
3,200) 
 0 (0 – 0) 
Cerebrovascular Disease n=6,123 
 
 
5,300 (0 – 
51,900) 
 
700 (200 – 
1,300) 
 
500 (0 – 4,300) 
 
900 (0 – 
3,300) 
 
0 (0, 0) 
Cerebrovascular Disease or 
Transient Ischaemic Attack 
n=8,451 
 
5,100 (0 – 
49,000) 
 
700 (200 – 
1,300) 
 
400 (0 – 2,100) 
 
900 (0 – 
3,300) 
 
0 (0 – 0) 
Heart Failure n=2,736 
 
 
5,600 (0 – 
50,700) 
 





970 (0 -  
3,300) 
 
0 (0 – 0) 
Hypertensive Diseases n= 5  
5,700 (100 – 
10,300) 
 
700 (400 – 
1,000) 
 
0 (0 - 0) 
  




0 (0 – 0) 
Ischaemic Heart Disease n=44,948 
 
 











0 (0 – 0) 
Peripheral Arterial Disease 
n=3,938 
 
6,500 (0 – 
58,700) 
 
700 (200 – 
1,300) 
 
280 (0 - 0) 
 1,000 (1000 – 
3,500) 
 










200 (0 – 0) 
 
900 (0 – 
3,100) 
 
0 (0 – 0) 
Transient Ischaemic Attack 
n=2,328 
 
4,600 (0 -  
45,000) 
 
700 (300 – 
1,300) 
 
200 (0 – 0) 
 
900 (0 – 
3,500) 
 
0 (0 - 0) 
Notes: These values do not sum to the total costs given in the main text.  They are regression based 
estimates. *These values reflect the age of incident event occurring typically after state pension 













Table 4: Mean annual costs; (cumulative); 3 year mortality; Incidence rates in people with type 2 
diabetes without previous history of CVD in Scotland 2010-2015 – based on study entry date 
(rounded to the nearest £100) 
 No incident CVD event 
Mean Cost £ and 95% CI 
Incident and subsequent CVD 
Mean Cost £ and 95% CI 
All  n=245428   
3 year mortality   25.25% 
Event Rate per 1,000 person years* 30.81 
Year 1  2,100 (1,000 - 6,100) 16,700 (6,700 - 41,700) 
Year 1&2 4,200 (2,000 - 11,900) 21,500 (9,000 - 50,900) 
Year 1,2&3 5,900 (2,800 - 16,500) 25,000 (10,700 - 57,100) 
< 60 years (n=104078)   
Year 1  1,400 (900 - 2,800) 11,200 (6,100 - 26,100) 
Year 1&2 3,000 (2,000 - 5,600) 14,400 (8,100 - 31,300) 
Year 1,2&3 4,000 (2,700 - 7,500) 16,800 (9,700 - 35,200) 
60- 69 years (n=68626)   
Year 1  1,900 (1,200 - 4,900) 13,800 (7,100 - 31,000) 
Year 1&2 4,000 (2,400 - 9,700) 17,400 (9,400 - 37,300) 
Year 1,2&3 5,600 (3,500 - 13,400) 20,100 (11,100 - 41,700) 
70- 79 years (n=51769)   
Year 1  2,900 (1,600 - 8,800) 17,400 (8,500 - 39,400) 
Year 1&2 5,900 (3,200 - 16,600) 22,900 (12,000 - 48,900) 
Year 1,2&3 8,300 (4,600 - 23,000)  27,000 (14,500 - 55,300) 
80+  (n=20955)   
Year 1  4,100 (2,000 - 12,400) 25,200 (12,200 - 57,800) 
Year 1&2 8,200 (4,200 - 23,400) 32,300 (16,700 - 68,700) 
Year 1,2&3 11,500 (6,000 - 32,200) 37,300 (20,000 - 76,900) 
   
Cerebrovascular Disease  (n=4172)                               
3 year mortality  30.37% 
Event Rate per 1,000 person years* 3.64 
Year 1   29,600 (14,700 - 62,300) 
Year 1&2  34,600 (17,600 - 71,600) 
Year 1,2&3  37,900 (19,400 - 78,700) 
Ischaemic Heart Disease (n=17594)                   
3 year mortality  21.26% 
Event Rate per 1,000 person years* 15.35 
Year 1   12,500 (6,500 - 27,500) 
Year 1&2  16,700 (8,600 - 35,900) 
Year 1,2&3  19,800 (10,200 - 42,100) 
Transient Ischaemic Attack (n=1370)                          
3 year mortality  17.88% 
Event Rate per 1,000 person years* 1.2 
Year 1   10,000 (5,100 - 21,400) 
Year 1&2  14,800 (7,700 - 30,000) 
Year 1,2&3  18,500 (9,700 - 36,700) 
Peripheral Arterial Disease (n=3114)                              
3 year mortality 27.65% 
Event Rate per 1,000 person years* 2.72 
Year 1   21,600 (10,300 - 47,900) 
Year 1&2  28,200 (13,500 - 61,100) 
Year 1,2&3  32,700 (15,700 - 69,100) 
Heart Failure (n=4205)                                             
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3 year mortality  38.10% 
Event Rate per 1,000 person years* 3.67 
Year 1   20,100 (9,200 - 43,300) 
Year 1&2  25,900 (11,700 - 54,700) 
Year 1,2&3  29,900 (13,600 - 62,000) 
Cardiac Arrhythmia (n=10260)                                       
3 year mortality  30.02% 
Event Rate per 1,000 person years* 8.95 
Year 1   17,600 (8,400 - 38,600) 
Year 1&2  22,900 (11,100 - 48,300) 
Year 1,2&3  26,700 (13,100 - 55,200) 
Hypertensive Diseases (n < 10)                                        
3 year mortality  66.67% 
Event Rate per 1,000 person years* 0.00 
Year 1   40,000 (28,700 - 50,600) 
Year 1&2  40,000 (28,700 - 50,600) 
Year 1,2&3  40,000 (28,700 - 50,600) 
Revascularisation Procedures (n = 3636)                        
3 year mortality  9.85% 
Event Rate per 1,000 person years* 3.17 
Year 1  12,100 (6,400 - 27,900) 
Year 1&2  15,000 (8,100 - 33,600) 
Year 1,2&3  17,500 (9,600 - 38,300) 
Cerebrovascular Disease/Transient Ischaemic Attack (n= 5435)  
3 year mortality  27.28% 
Event Rate per 1,000 person years* 1.2 
Year 1   15,700 (8,900 - 31,800) 
Year 1&2  21,000 (2,000 - 42,400) 
Year 1,2&3  24,900 (13,500 - 48,700) 
















Table 5: Mean cost (cumulative) by cost component and CVD type (rounded to the nearest £100) 
Cost Type / CVD type  Costs (£) over 12 months  
Mean (95% CI)*  
Costs (£) over 24 months  
Mean (95% CI)* 
Costs (£) over 36 months  
Mean (95% CI)* 
Secondary care    
Cerebrovascular Disease  25,000 (700 - 
114,900) 
28,300 (700 - 
129,500) 
30,600 (800 - 
139,100) 
Ischaemic Heart Disease  11,000 (100 - 63,400) 13,900 (100 - 80,600) 16,100 (200 - 91,200) 
Transient Ischaemic Attack  8,600 (100 - 65,200) 12,000 (100 - 78,900) 14,700 (200 - 90,200) 
Peripheral Arterial Disease  
18,500 (100 - 98,300) 
23,400 (100 - 
116,800) 
26,500 (200 - 
131,300) 
Heart Failure  
17,000 (100 - 79,900) 
21,100 (200 - 
101,900) 
24,000 (400 - 
112,600) 
Cardiac Arrhythmia  
15,600 (100 - 84,200) 
19,300 (100 - 
100,700) 
22,100 (200 - 
122,500) 
Hypertensive Diseases  16,200 (3,800 - 
32,000) 
27,100 (14,600 - 
34,300) 
27,200 (14,700 - 
34,400) 
Revascularisation Procedures  11,200 (100 - 74,800) 13,100 (100 - 86,300) 14,700 (200 - 99,200) 
Cerebrovascular Disease or TIA  21,100 (100 - 
105,800) 
24,500 (200 - 
121,100) 
26,900 (400 - 
130,000) 
Primary care    
Cerebrovascular Disease 600 (0 - 1,200) 1,100 (0 - 2,300) 1,500 (0 - 3,500) 
Ischaemic Heart Disease  500 (0 - 1,200) 1,000 (0 - 2,200) 1,500 (0 - 3,300) 
Transient Ischaemic Attack 600 (200 - 1,200) 1,200 (200 - 2,500) 1,800 (200 - 3,600) 
Peripheral Arterial Disease 600 (0 - 1,200) 1,100 (0 - 2,400) 1,600 (0 - 3,500) 
Heart Failure  600 (0 - 1,200) 1,100 (0 - 2,500) 1,600 (0 - 3,700) 
Cardiac Arrhythmia  600 (0 - 1,200) 1,100 (0 - 2,300) 1,500 (0 - 3,300) 
Hypertensive Diseases  500 (100 - 700) 800 (200 - 1,400) 1,100 (200 - 2,100) 
Revascularisation Procedures  500 (100 - 1,000) 1,000 (100 - 2,100) 1,400 (100 - 3,100) 
Cerebrovascular Disease or TIA  600 (0 - 1,200) 1,100 (0 - 2,300) 1,600 (0 - 3,500) 
Residential care    
Cerebrovascular Disease  700 (0 - 13,500) 1,300 (0 - 20,000) 1,700 (0 - 25,000) 
Ischaemic Heart Disease  300 (0 - 0 ) 500 (0 - 0) 700 (0 - 0) 
Transient Ischaemic Attack  300 (0 - 0) 500 (0 - 0) 700 (0 - 0) 
Peripheral Arterial Disease  300 (0 - 0) 500 (0 - 1,400) 800 (0 - 3,900) 
Heart Failure  400 (0 - 1,300) 600 (0 - 4,000) 800 (0 - 5,300) 
Cardiac Arrhythmia  500 (0 - 3,200) 900 (0 - 7,100) 1,200 (0 - 10,800) 
Hypertensive Diseases  0 (0 - 0) 4,100 (0 - 11,600) 4,100 (0 - 11,600) 
Revascularisation Procedures  100 (0 - 0) 300 (0 - 0) 400 (0 - 0) 
Cerebrovascular Disease or TIA 600 (0 - 10,200) 1,100 (0 - 15,600) 1,500 (0 - 19,300) 
Prescriptions    
Cerebrovascular Disease  800 (0 - 2,900) 1,300 (0 - 5,200) 1,600 (0 - 6,800) 
Ischaemic Heart Disease  900 (0 - 3,100) 1,600 (0 - 5,900) 1,900 (0 - 7,700) 
Transient Ischaemic Attack 800 (0 - 3,200) 1,500 (0 - 6,400) 1,800 (0 - 7,700) 
Peripheral Arterial Disease  900 (0 - 3,100) 1,600 (0 - 5,900) 2,000 (0 - 7,900) 
Heart Failure 900 (0 - 3,500) 1,600 (0 - 6,500) 2,000 (0 - 8,400) 
Cardiac Arrhythmia  800 (0 - 3,000) 1,400 (0 - 5,400) 1,700 (0 - 7,000) 
Hypertensive Diseases 2,000 (900 - 3,000) 3,000 (3,000 - 3,100) 4,100 (3,200 - 5,000) 
Revascularisation Procedures 800 (0 - 3,000) 1,300 (0 - 5,200) 1,700 (0 - 6,800) 
Cerebrovascular Disease or TIA 800 (0 - 3,000) 1,400 (0 - 5,500) 1,700 (0 - 7,100) 
Productivity    
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Cerebrovascular Disease 600 (0 - 6,200) 700 (0 - 7,000) 700 (0 - 7,700) 
Ischaemic Heart Disease 300 (0 - 2,200) 300 (0 - 2,700) 400 (0 - 3,100) 
Transient Ischaemic Attack  100 (0 - 1,000) 200 (0 - 1,700) 200 (0 - 2,400) 
Peripheral Arterial Disease  600 (0 - 6,100) 800 (0 - 7,700) 900 (0 - 8,800) 
Heart Failure  300 (0 - 3,500) 400 (0 - 4,300) 500 (0 - 5,000) 
Cardiac Arrhythmia  200 (0 - 2,300) 300 (0 - 2,900) 300 (0 - 3,300) 
Hypertensive Diseases  100 (0 - 400) 4,800 (0 - 13,800) 4,800 (0 - 13,800) 
Revascularisation Procedures  600 (0 - 5,400) 700 (0 - 6,200) 800 (0 - 7,100) 
Cerebrovascular Disease or TIA  500 (0 - 5,600) 600 (0 - 6,100) 600 (0 - 6,900) 
*Non-parametric CIs have been estimated  
 
Caption for Figure 2. Contribution to average total costs of different cost categories over years 
1,2&3 for people experiencing an index CVD event (left panel) and those not experiencing an index 
CVD event (right panel) 
 



























































Definition of established CVD  
Established CVD was defined as having codes for any cause of admission for chronic ischaemic heart 
disease (ICD-10 I20-I25), cerebrovascular disease including transient ischaemic attack (ICD-10 I60-63, 
I66, I69 & G45), peripheral arterial disease (ICD-I70.2 and I73.9), heart failure (I11.0, I13 I50), cardiac 
arrhythmia (I48, I49), hypertensive heart disease (I13.0, I15.0) or procedure codes for 
revascularisation procedures of coronary, carotid or lower limb arteries. In addition, primary care 
records were also queried for corresponding Read codes for coronary heart disease, cerebrovascular 




























Table A1: Demographic characteristics and risk factors by CVD status in people with Type 2 diabetes  
 
Parameter Established CVD 
73,037(29.84) 





244,752 Male N (%) 44363(60.74) 75951(53.70) 17664(58.32) 137978(56.37) 
Female N (%) 28674(39.26) 65477(46.30) 12623(41.68) 106774(43.63) 
Mean (SD)     
Age at index date (years) 72.2(10.6) 64.9(12.5) 62.2(12.6) 66.7(12.5) 
Age at diabetes diagnosis (years) 61.6(11.8) 55.8(12.5) 57.5(12.6) 57.7(12.6) 
Diabetes duration (years) 10.6(7.6) 9.2(6.5) 4.7(4.6) 9.0(6.9) 
Systolic BP (mmHg) 132.0(16.2) 135.0(14.4) 125.6(12.1) 133.0(15.0) 
Diastolic BP (mmHg) 72.7(9.8) 76.3(9.5) 73.9(8.1) 75.0(9.6) 
Total Cholesterol (mmol/L) 4.0(1.1) 4.3(1.1) 4.4(1.0) 4.3(1.1) 
LDL Cholesterol (mmol/L) 2.0(0.8) 2.2(0.9) 2.3(0.9) 2.1(0.9) 
HDL Cholesterol (mmol/L) 1.1(0.3) 1.2(0.4) 1.3(0.4) 1.2(0.4) 
HbA1c (mmol/mol) 58.6(17.5) 60.5(18.2) 52.0(11.4) 59.0(17.5) 
HbA1c (%) 9.3(3.5) 9.7(3.5) 8.4(2.5) 9.3(3.5) 
Weight (Kg) 89.3(19.0) 92.8(20.6) 83.3(17.8) 90.7(20.1) 
BMI (Kg/m2) 31.4(6.0) 32.8(6.5) 28.8(5.4) 31.9(6.4) 
Albumin Creatinine Ratio 1.5(0.5,5.1) 1.1(0.3,3.0) 0.6(0.0,1.2) 1.1(0.3,3.1) 
Albuminuric Status N (%)     
Normo 42093(68.43) 92326(77.26) 21718(98.28) 156137(76.87) 
Micro 15941(25.91) 23907(20.01) 363(1.64) 40211(19.80) 
Macro  3482(5.66) 3261(2.73) 16(0.07) 6759(3.33) 
Renal status N (%)     
CKDEpi CKD Stage 1 12944(18.22) 49593(35.90) 12175(44.03) 74712(31.54) 
CKDEpi CKD Stage 2 33587(47.27) 61661(44.63) 14985(54.19) 110233(46.54) 
CKDEpi CKD Stage 3 21477(30.23) 24790(17.94) 479(1.73) 46746(19.73) 
CKDEpi CKD Stage 4/5 3049(4.29) 2117(1.53) 15(0.05) 5181(2.19) 
Current Smoker N (%) 13283(18.22) 29502(20.88) 1828(6.20) 44613(18.31) 
Socio-Economic Status1 N (%)    
Not known 198(0.27) 472(0.33) 115(0.38) 785(0.32) 
SIMD-1 9509(13.02) 16718(11.82) 2979(9.84) 29206(11.93) 
SIMD-2 9352(12.80) 16696(11.81) 3141(10.37) 29189(11.93) 
SIMD-3 8906(12.19) 16542(11.70) 3022(9.98) 28470(11.63) 
SIMD-4 8304(11.37) 15683(11.09) 3094(10.22) 27081(11.06) 
SIMD-5 7587(10.39) 14522(10.27) 3069(10.13) 25178(10.29) 
SIMD-6 6949(9.51) 14132(9.99) 2956(9.76) 24037(9.82) 
SIMD-7 6451(8.83) 13375(9.46) 3094(10.22) 22920(9.36) 
SIMD-8 5954(8.15) 12301(8.70) 3082(10.18) 21337(8.72) 
SIMD-9 5445(7.46) 11498(8.13) 2960(9.77) 19903(8.13) 
SIMD-10 4382(6.00) 9489(6.71) 2775(9.16) 16646(6.80) 
Health Board     
Argyll 6240(8.54) 11730(8.30) 2526(8.34) 20496(8.38) 
Ayrshire and Arran 6484(8.88) 11142(7.88) 2282(7.54) 19908(8.14) 
Borders 1672(2.29) 3204(2.27) 838(2.77) 5714(2.34) 
Dumfries & Galloway 2280(3.12) 4530(3.20) 815(2.69) 7625(3.12) 
England / Wales / Northern Ireland <10(0.01) 45(0.03) <10(0.02) 61(0.02) 
Fife 5344(7.32) 10711(7.58) 2282(7.54) 18337(7.49) 
Forth Valley 4077(5.58) 8253(5.84) 1516(5.01) 13846(5.66) 
Glasgow 11378(15.58) 20770(14.69) 4558(15.05) 36706(15.00) 
Grampian 6960(9.53) 14000(9.90) 3203(10.58) 24163(9.87) 
Highland 3070(4.20) 5626(3.98) 1017(3.36) 9713(3.97) 
Lanarkshire 9406(12.88) 18234(12.90) 3957(13.07) 31597(12.91) 
Lothian 9388(12.85) 19645(13.90) 4360(14.40) 33393(13.65) 
Orkney 240(0.33) 499(0.35) 144(0.48) 883(0.36) 
Shetland 258(0.35) 599(0.42) 108(0.36) 965(0.39) 
Tayside 5926(8.11) 11745(8.31) 2555(8.44) 20226(8.27) 
Western Isles 304(0.42) 645(0.46) 117(0.39) 1066(0.44) 
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1Socio-Economic status is measured using the Scottish Index of Multiple Deprivation (SIMD), represented as deciles, where 
1 represents the most deprived areas and 10 represents the least deprived areas. 
 
 










Age at index date 
Median (IQR) 
60.9 (13.1) 69.2 (11.3) 
Age at diabetes diagnosis   56.8 (13.0) 62.2 (12.4) 
Diabetes duration (years) (Median, IQR) 1.5(0.0,6.6) 5.3(0.8,10.5) 
Systolic BP (mmHg) 136.1(16.5) 137.4(17.8) 
Diastolic BP (mmHg) 78.8(10.3) 75.9(10.7) 
Total Cholesterol (mmol/L) 4.8(1.3) 4.4(1.2) 
LDL Cholesterol (mmol/L) 2.4(1.0) 2.3(1.0) 
HDL Cholesterol (mmol/L) 1.2(0.4) 1.2(0.4) 
HbA1c (mmol/mol) 60.7(20.3) 59.2(19.2) 
HbA1c (%) 7.7(4.0) 7.6(3.9) 
Weight (Kg) 91.0(21.1) 87.9(20.2) 
BMI  Kg/m2  
Median (IQR) 
32.2(6.7) 31.4(6.4) 
Albumin Creatinine Ratio (μg/mg) 1.0(0.4,2.5) 1.3(0.6,3.8) 
Renal Status   
CKDEpi CKD Stage 1 79832(38.46) 7068(20.44) 
CKDEpi CKD Stage 2 96202(46.35) 16762(48.46) 
CKDEpi CKD Stage 3 29545(14.23) 9768(28.24) 
CKDEpi CKD Stage 4/5  1997(0.96) 989(2.86) 
Current Smoker 52638(25.05) 9377(26.55) 
SIMD Decile1 (N, %)   
SIMD-1 4342(12.29) 24657(11.74) 
SIMD-2 4399(12.45) 24543(11.68) 
SIMD-3 4204(11.90) 24064(11.45) 
SIMD-4 3955(11.20) 23065(10.98) 
SIMD-5 3778(10.70) 21496(10.23) 
SIMD-6 3384(9.58) 20730(9.87) 
SIMD-7 3228(9.14) 20037(9.54) 
SIMD-8 3052(8.64) 18505(8.81) 
SIMD-9 2645(7.49) 17495(8.33) 
SIMD-10 2232(6.32) 14781(7.04) 
Not known 103(0.29) 733(0.35) 
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1Socio-Economic status is measured using the Scottish Index of Multiple Deprivation (SIMD), represented as deciles, where 
1 represents the most deprived areas and 10 represents the least deprived areas. 
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